Ligand (LGND) Completes Acquisition of Pfenex Inc. (PFNX) Oct 1, 2020 08:26AM
Ligand Pharma (LGND) Announces Expiration of Tender Offer for Shares of Pfenex (PFNX), Expects Merger to Close on October 1 Sep 30, 2020 08:04AM
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc. Sep 30, 2020 08:00AM
Ligand Pharma (LGND) Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc. (PFNX) Aug 31, 2020 09:04AM
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc. Aug 31, 2020 09:00AM
View Older Stories

Aug 10, 2020 05:37PM Ligand Pharma (LGND) to Acquire Pfenex (PFNX) for $12 Per Share in Cash Plus CVR
Aug 10, 2020 05:36PM Ligand to Acquire Pfenex Inc.
Aug 6, 2020 04:05PM Pfenex Reports Second Quarter 2020 Results and Provides Business Update
Jul 20, 2020 08:30AM Pfenex to Announce Second Quarter Financial Results on August 6
Jun 26, 2020 02:06PM Pfenex (PFNX) Announces Positive European CHMP Opinion for PF708 and New Partnership in Latin America, and Provides CRM197 Business Update
Jun 26, 2020 02:05PM Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business Update
Jun 12, 2020 08:00AM Pfenex Announces U.S. Commercial Launch of Teriparatide Injection
Jun 5, 2020 09:00AM Pfenex to Participate in the William Blair Growth Stock Conference
May 7, 2020 04:05PM Pfenex Reports First Quarter 2020 Results and Provides Business Update
Apr 24, 2020 04:05PM Pfenex to Announce First Quarter 2020 Financial Results on May 7
Apr 14, 2020 05:08PM Pfenex (PFNX) Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence Determination
Apr 14, 2020 05:04PM Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence Determination
Mar 11, 2020 04:05PM Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update
Feb 26, 2020 05:03PM Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11
Dec 18, 2019 08:09AM Pfenex (PFNX) Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals
Dec 18, 2019 08:00AM Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals
Nov 20, 2019 04:10PM Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference
Nov 19, 2019 04:10PM Pfenex to Present at the Evercore ISI HealthCONx Conference 2019
Nov 13, 2019 04:40PM Pfenex Announces Management Change
Nov 7, 2019 04:05PM Pfenex Reports Third Quarter 2019 Results and Provides Business Update
Nov 6, 2019 04:10PM Pfenex to Present at the Jefferies 2019 London Healthcare Conference
Oct 24, 2019 04:30PM Pfenex to Announce Third Quarter 2019 Financial Results on November 7th
Oct 14, 2019 08:04AM Pfenex (PFNX) Announces Positive Results for PF708 Comparative Use Human Factors Study
Oct 14, 2019 08:00AM Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study
Oct 11, 2019 08:01AM Pfenex (PFNX) Provides Update for PF708 Outside the U.S.
Oct 11, 2019 08:00AM Pfenex Provides Update for PF708 Outside the United States
Oct 7, 2019 06:20AM Pfenex (PFNX) Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
Oct 7, 2019 05:00AM Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
Sep 16, 2019 04:05PM Pfenex to Present at the Cantor Healthcare Conference
Sep 10, 2019 04:05PM Pfenex to Participate in the Oppenheimer Fall Summit
Sep 5, 2019 04:05PM Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals
Sep 4, 2019 04:05PM Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board
Aug 8, 2019 04:05PM Pfenex Reports Second Quarter 2019 Results and Provides Business Update
Aug 1, 2019 08:20AM Pfenex (PFNX), Arcellx Announce a Development, Evaluation and License Agreement
Aug 1, 2019 08:10AM Pfenex and Arcellx Announce a Development, Evaluation and License Agreement
Jul 25, 2019 04:10PM Pfenex to Announce Second Quarter 2019 Financial Results on August 8
Jun 5, 2019 04:05PM Pfenex to Participate at the JMP Securities Life Sciences Conference
May 30, 2019 08:03AM Pfenex (PFNX), Alvogen Announce EMA Accepts MAA for PF708
May 30, 2019 08:00AM Pfenex and Alvogen Announce European Medicines Agency Accepts Marketing Authorization Application for PF708
May 9, 2019 04:05PM Pfenex Reports First Quarter 2019 Results and Provides Business Update
Apr 25, 2019 04:05PM Pfenex to Announce First Quarter 2019 Financial Results on May 9
Apr 23, 2019 08:05AM Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board
Apr 11, 2019 08:05AM Pfenex Announces Successful Expiration of 45 Day Waiting Period Under Hatch-Waxman Act
Mar 27, 2019 04:05PM Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
Mar 26, 2019 04:05PM Pfenex to Present at the 18th Annual Needham Healthcare Conference
Mar 18, 2019 04:05PM Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference
Mar 18, 2019 08:05AM Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer
Mar 11, 2019 04:05PM Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
Mar 11, 2019 12:05PM Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
Feb 28, 2019 08:05AM Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW
View Older Stories